Elife E-bikesWe design and import components directly from industries (Germany etc.) and handmake e-bikes in Norway. This is the 3 rd year for us, we have our shop in Oslo and started our focus on developing&producing. We have distributors in Norway and Iceland. Our advantage is that all our competitors can be potential partners. In 2018, we have handmade the lightest three-seater "e-bike-car" in the world - iCloud. It allows 2 People to pedal at the same time. It protects you from bad weather & has a 150L trunk. Its battery range is 200km.

VR is changing the way we learn with spacial mnemonics encoding trigging memory intimacy and presence - VR tech makes it possible to learn better and faster. Making View has the smartest and boldest people with an international company track record and solutions developed in cooperation with researches and clients. Making View is the improvisation master in the VR tech world creating harmonious learning environments - We will provide a scalable business model based on annual licenses.

Vi er en nøytral koblingsaktør mellom innovasjonsmiljø, offentlige støttespillere, gründere, etablert næringsliv, investorer og akademia. Vi legger til rette for å utvikle flere gode gründere, vekstkraftige bedrifter og innovative næringsmiljøer. CMN gjør dette ved å skape møteplasser og forretningsmuligheter, hvor vi kobler de riktige ressursene og menneskene. Vi er særlig opptatt av å bidra til: • økt verdiskaping og at flere start-ups lykkes med vekst og utvikling • å oppfylle FNs bærekraftmål • lik kjønnsbalanse og økt kvinneandel i styrer, ledelse og gründerskap • at Connect sin globale organisasjon blir en støtte for norske vekstselskaper

The job search agent that works for you.

HistorieDroneverkstedet ble etablert i 2011 av Vitaliy Slettevoll som ett hobby prosjekt. På grunn av den enorme utviklingen i RPAS bransjen har vedkommende de siste tre år jobbet som RPAS inspektør i Luftfartstilsynet, mens andre har tatt seg av driften av droneverkstedet Nå i 2018 er midlertidig Slettevoll tilbake og har tatt over driften igjen. Vårt nye verksted er lokaliser i Drammen på Brakerøya og vi ønsker velkommen til både gamle og nye kunder. KvalitetKvalitet er ikke bare ett ord for oss. Vi i droneverkstedet jobber kontinuerlig med å forbedre oss. Vår mål er å kunne tilfredstille til enhver tid produkt- og servicekvalitet basert på krav fastsatt av våre kunder, våre egne kvalitetsstandarder og av myndighetene. Service Gjennom kontinuerlig satsing på forbedring og utvikling av våre arbeidsmetoder og medarbeidernes kompetanse. Er vi i stand til å kunne tilby bransjets beste service til våre kunder, og vi strekker oss alltid lit lengre for å møte kundenes serviceforventninger. SikkerhetSikkerhet er prioritet nummer en i norsk luftfart. Gjennom hver ledd i vårt arbeid sørger vi for at våre kunder blir bidragsytere til den positive utviklingen i norsk luftfart.

OptoScale supplies fish farmers with precise and relevant data empowering them to make decision that improve productivity, sustainability, and animal welfare. Our data informs fish farmers about how their production is going, by accurately measuring the size of fish, growth, welfare status, and parasite counting. Our head office is in Trondheim, Norway, and we deliver to our great customers around the world. We are continuously interested in hiring great people across most of our functions: HW development, AI/ML, electronics, sales and customer success.

ENVE leverer morgendagens datarom for sømløse og effektive transaksjoner. Ved blant annet automatisering av rapportgenerering og optimalisering av informasjonsflyt tilbyr vi våre kunder et markedsledende arbeidsverktøy for due diligence-prosesser og transaksjoner. ENVE skal gå i bresjen for å bidra til digitalisering og modernisering av transaksjonsmarkedet.

Move is an IT infrastructure consulting company and system integrator covering the areas of Network and Security, Virtualization, Database and OS platforms, and high-end server/storage. Move delivers: High expertise advisor and consultancy services Design and implementation of complex projects Diversified service and support services Project Management IT-solutions

eCommerce, B2B, and product development towards tactical, outdoor, and lifestyle products. Office and warehouse in Oslo and eCommerce presence 3 in Norway, Sweden, and Finland. 25 employees and 100MNOK revenue in 2018. We've been growing about 50% yearly over the last three years and aim to continue growing at the same speed. The young data-driven organization with ambitions to become the biggest player within our niche. Come and join us!

CardiNor AS er et norsk bioteknologiselskap etablert for å håndtere kommersialiseringen av secretoneurin, en ny biomarkør test for hjertekar sykdom. Vår innovasjon er en ny og proprietær hjertekar test – secretoneurin. Secretoneurin er vist å ha sterk prognostisk nytteverdi hos pasienter med hjertesvikt, og den har et særskilt stort potensial hos pasienter med hjerterytmeforstyrrelser (arytmi). Hjertekar sykdom er fortsatt den viktigste dødsårsaken i verden i dag. Ingen av de kjent og etablerte biomarkørene for hjertekar sykdom er til særlig hjelp i valg av medisinske, og eller kirurgiske behandlingsmetoder for å forhindre livstruende hjerterytmeforstyrrelser. Selskapet utvikler nå en brukervennlig forskningstest for å måle secretoneurin blod som vil markedsført og solgt gjennom et nettverk av distributører i Europa og USA. Dette etterfulgt av introduksjonen av et CE-merket produkt for klinisk bruk i Europa og regulatorisk godkjenning i USA. CardiNor-ledelsen har inngående kunnskap om og erfaring fra bioteknologi og diagnostisk industri som dekker hele livssyklus fra oppstart til exit. CardiNor samarbeider med verdensledende akademiske institusjoner og opinionsledere og industri i å utvikle og dokumentere biomarkør testen.

Oncoinvent AS is a privately held Norwegian company established in 2010. The company is committed to developing new innovative products to provide better treatment options to cancer patients. The innovations being developed by Oncoinvent AS are a result of the extensive experience with the development of radionuclide-based cancer treatments of two of the founders, Dr. Roy H. Larsen and Professor of clinical oncology Øyvind S. Bruland. Larsen and Bruland are the inventors of the first FDA and EMA-approved alpha-emitting pharmaceutical product Xofigo® (Bayer AG), as well as of the beta-emitting radio-immunotherapeutic product candidate Betalutin® (Nordic Nanovector ASA). Oncoinvent's lead product candidate, Radspherin®, is a novel alpha-emitting radioactive microsphere designed for the treatment of metastatic cancers in body cavities. Radspherin® has been shown to cause a significant reduction in tumor cell growth. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be the treatment of peritoneal carcinomatosis. Clinical development will be conducted in collaboration with European and American clinical research centers.

An intracellular approach to diagnostics – changing the way diagnostics approach blood tests. Pre Diagnostics is the first diagnostics company to focus on intracellular measurements of disease-specific biomarkers inside the blood cells. We extract disease-relevant information from biomarkers located inside specific blood cells called monocytes to provide actionable results for patients and practitioners.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

LangO is changing the way companies deliver English language training to their employees online. We do this through a blended learning solution; a combination of live virtual lessons (Group Live Lessons and One-to-One) complemented by our on-demand micro-learning activities. Our responsive web app brings in the best-qualified teachers from around the world, custom-made LangO lesson content based on client's needs, and a scalable tech stack enabling employees to learn effectively on any device, at any time.

Excitus is set up to develop, manufacture and sell medical suction products based on its revolutionary, patent-pending mobile suction platform. Products will span from professional hand-held tools for paramedics to consumer devices in a private home and stored together with the defibrillator at supermarkets, stadiums, etc. The platform enables a higher survival rate at cardiac arrests, yet at the same time, it provides a razor/razorblade business model unseen in this area.